LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced on July 31, 2026, that it has entered into an agreement with the Venezuelan Institute for Scientific Research (IVIC) to develop a digital platform module. The module is designed to support access to designated laboratory and scientific services, potentially streamlining processes for authorized business and institutional users.
The agreement, facilitated through LataMed AI's Venezuelan subsidiary LATAMEDAI VE, outlines a collaboration to design, develop, test, and implement a digital interface. This interface would allow authorized users to request available laboratory services, schedule appointments, monitor the status of submitted requests, access approved reports and documentation, and complete authorized payment-related processes. The proposed module aims to provide a centralized digital workflow for organizations in sectors such as healthcare, pharmaceuticals, food production, agriculture, and related industries.
The specific services to be offered through the platform will be determined by IVIC and implemented according to technical, operational, security, and legal requirements established by both parties. LataMed AI will begin working with IVIC to define functional requirements, user-access procedures, data architecture, payment workflows, document-management capabilities, and a phased testing and implementation process. They will also establish procedures for handling, transmitting, storing, and authorizing access to laboratory-related information.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI, commented, "This agreement represents an opportunity to apply our technology to an important area of scientific and enterprise service delivery. Our objective is to work with IVIC to develop a responsible digital framework that makes it easier for authorized users to request services, manage appointments, monitor processes, and access approved information through a centralized platform."
Management believes this initiative could expand LataMed AI's capabilities beyond patient-facing telemedicine, demonstrating how its technology can support institutional and enterprise workflows involving healthcare, scientific services, laboratory coordination, and digital documentation. This aligns with the company's broader strategy of developing digital infrastructure that connects patients, healthcare professionals, pharmacies, insurers, payment providers, wellness organizations, institutions, and other participants in the healthcare and scientific-services ecosystem.
If successfully implemented, the module could potentially be adapted for other institutional and enterprise service environments in Venezuela and Latin America. However, any future expansion would be subject to separate agreements, technical readiness, regulatory requirements, and the needs of participating institutions. The agreement establishes the framework for development and evaluation but does not guarantee a specific implementation date, user adoption level, service volume, revenue, profitability, or expansion to additional institutions.
LataMed AI is also developing AI-supported platforms named CardioAI, PulmoAI, and NeuroAI, intended to assist healthcare professionals in evaluating and managing cardiovascular, pulmonary, and neurological health information. These platforms remain subject to continued development and regulatory approvals. The company's technologies are under development and are not intended to replace the independent professional judgment of qualified professionals.
For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
